Recruiting × Biliary Tract Neoplasms × Gastrointestinal × Clear all Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Recruiting
100 enrolled
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Recruiting
200 enrolled
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Recruiting
100 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting
1,000 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2 Recruiting
135 enrolled
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Phase 2 Recruiting
64 enrolled
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Recruiting
60 enrolled
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 3 Recruiting
286 enrolled
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Phase NA Recruiting
360 enrolled
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
27 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2 Recruiting
294 enrolled
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 Recruiting
171 enrolled
DESTINY-BTC01
Phase 3 Recruiting
620 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 Recruiting
224 enrolled
DVDMS
Phase 2 Recruiting
30 enrolled
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Phase 1/2 Recruiting
60 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
Beacon-BTC
Phase 3 Recruiting
480 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1/2 Recruiting
50 enrolled
ARCBile
Recruiting
1,000 enrolled
BRAVE
Phase NA Recruiting
120 enrolled
FAPi-2
Recruiting
60 enrolled
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase 1 Recruiting
20 enrolled
LNCB74-01
Phase 1 Recruiting
145 enrolled
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 Recruiting
60 enrolled
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/2 Recruiting
103 enrolled
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Phase 2 Recruiting
300 enrolled
The Study of Association of Helicobacter Infections in Biliary Tract Cancers
Recruiting
250 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Phase 1 Recruiting
15 enrolled
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Phase 2 Recruiting
45 enrolled
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 Recruiting
27 enrolled
SEVILLA
Phase 2 Recruiting
72 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
LapTAP
Phase NA Recruiting
48 enrolled
GENTIS
Recruiting
61 enrolled
PILOT-BTC
Phase 2 Recruiting
100 enrolled
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
Phase NA Recruiting
204 enrolled
BABEL
Recruiting
560 enrolled
TRAP-BTC
Phase 2 Recruiting
24 enrolled
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/2 Recruiting
80 enrolled
CARPEGIEM
Phase NA Recruiting
128 enrolled
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Phase NA Recruiting
120 enrolled